Haemonetics Corporation (HAE)

Over the past six months, Haemonetics' share price has outperformed the S&P500 Index by +12.18%, but as of May 7, 2026, shares were trading -6.27% below their 200-day moving average. On May 7, 2026, Haemonetics reported its fourth-quarter and fiscal year 2026 financial results, surpassing analyst expectations, which led to the stock trading up 11.8% during mid-day trading. On March 11, 2026, Citigroup cut its price target on Haemonetics from $75.00 to $70.00 and maintained a "neutral" rating. On April 13, 2026, Mizuho cut its price target on Haemonetics from $80.00 to $70.00 but maintained an "outperform" rating. On February 6, 2026, Robert W. Baird set an $81.00 price target, and BTIG Research reiterated a "buy" rating with an $88.00 price target. On January 10, 2026, Wall Street Zen upgraded Haemonetics from a "hold" to a "buy" rating. In December 2023, the acquisition of OpSens Inc. added the Sensor-Guided Technologies product line to Haemonetics' portfolio.

Product revenue for Haemonetics is primarily driven by the demand for disposable blood component collection and processing sets and the related equipment. While specific seasonal fluctuations are not detailed, the company's operations are tied to blood and plasma donation industries, as well as surgical procedures in hospitals. Demand for blood and plasma products can be influenced by factors such as public health campaigns, holiday donation patterns, and disease outbreaks. Less invasive surgeries have reduced demand for autotransfusion in some procedures, while increased access to healthcare in emerging economies has provided new markets.

Haemonetics Corporation is a global medical technology company founded in 1971 that focuses on enhancing healthcare quality, effectiveness, and efficiency. It provides medical products and solutions for blood and plasma component collection, surgical suites, and hospital transfusion services, operating in the Healthcare sector, specifically the Medical Devices and Instruments industry. The company's business is divided into three segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection systems, disposable products, and donor management software. The Blood Center segment provides apheresis solutions for automated blood collection. The Hospital segment includes Interventional Technologies (Vascular Closure, Sensor Guided Technologies, and Esophageal Protection products) and Blood Management Technologies (Hemostasis Management, Cell Salvage, and Transfusion Management products).

Haemonetics Corporation has a global presence with offices in 16 countries and markets its products in over 50 countries. Its revenue is nearly equally derived from Asia, Europe, and the Americas. The company's headquarters are located in Boston, Massachusetts, having relocated from Braintree, Massachusetts, in 2019.

Haemonetics maintains a solid brand reputation and strong market presence, recognized for its innovative product portfolio in hospital technologies, plasma collection, and blood component products. Its focus on improving patient care and reducing healthcare costs contributes to its positive standing. Recent financial performance, including strong growth in blood management technologies, underscores the demand for its advanced medical technology. Strategic acquisitions and product launches are expected to position the company for continued growth. While there has been some scrutiny of the interventional technologies segment and challenges in the blood center segment due to competition, the majority of revenue comes from higher-margin businesses, contributing to a positive stock outlook.

Haemonetics Corporation is a publicly traded company with institutional investors holding the largest percentage of its stock. As of May 1, 2026, 335 institutional owners and shareholders held a total of 50,658,145 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Neuberger Berman Group LLC, Aqr Capital Management Llc, State Street Corp, Arrowstreet Capital, Limited Partnership, Fmr Llc, Citadel Advisors Llc, Holocene Advisors, LP, and Goldman Sachs Group Inc. BlackRock Inc. is the largest individual shareholder, owning 5.82 million shares, representing 12.53% of the company. Institutional ownership is approximately 97.07%, while insider ownership is around 2.93%.